AN2 Therapeutics, Inc. (ANTX) vs Surrozen, Inc. (SRZN)
A side-by-side comparison of AN2 Therapeutics, Inc. and Surrozen, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANTX
AN2 Therapeutics, Inc.
$5.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SRZN
Surrozen, Inc.
$26.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ANTX vs SRZN
growth of $100 · dividends reinvested · last 5yANTX -63.6% (-18.3%/yr)SRZN -41.5% (-10.2%/yr)SRZN compounded faster over this window
ANTX SRZN
ANTX vs SRZN: by the numbers
- •SRZN is the larger company ($197M vs $183M market cap).
- •Both run net losses; ANTX's is the smaller (0.00% vs -2885.33% net margin).
Metrics side by side
Valuation
| Metric | ANTX | SRZN |
|---|---|---|
| P/S ratio | N/A | 17.13 |
| P/B ratio | 2.41 | N/A |
Profitability
| Metric | ANTX | SRZN |
|---|---|---|
| Gross margin | 0.00% | 84.56% |
| Operating margin | 0.00% | -1210.58% |
| Net margin | 0.00% | -2885.33% |
| ROE | -47.78% | N/A |
| ROIC | -51.01% | -41.61% |
Growth (annualized)
| Metric | ANTX | SRZN |
|---|---|---|
| Total return CAGR (5Y) | N/A | -20.80% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.